| |
The BD FACSymphony A5 SE Cell Analyzer adds high-sensitivity detectors to detect the full spectrum of emitted light. Unmix spectral data live, all while retaining the flexibility of familiar compensation-based workflows. Learn more.
|
|
Today's Big NewsNov 7, 2022 |
| By James Waldron It may have made its name—and fortune—with a COVID shot, but mRNA pioneer BioNTech is thinking bigger for 2023, with up to five trials for infectious disease vaccines set to enter the clinic. |
|
|
|
By Max Bayer Flagship-founded Repertoire Immune Medicines is completely reshuffling following news that it had laid off nearly half of its staff. The company disclosed Monday that it had culled its top two assets and was replacing its founding CEO. |
By Gabrielle Masson With fleshed-out phase 2 data, Amgen says it will launch a phase 3 for its heart drug olpasiran by the end of this year. |
By Annalee Armstrong Verve Therapeutics’ lead gene editing candidate has lost some steam after running into an FDA clinical hold. |
By James Waldron Inhibikase Therapeutics has been left stumped and its stock sunk after the FDA unexpectedly placed a clinical hold on its midstage Parkinson’s drug. |
By Helen Floersh An effort to map the way the brains of those with autism are genetically unique from neurotypical individuals has found that the differences go well beyond regions involved in social behavior and language. |
By Paige Minemyer We're honoring 10 women making a difference in pushing healthcare to the future. This year's list covers the breadth of the industry, from providers to payers to health tech, and represents some of the industry's largest companies as well as up-and-coming innovators. |
By Angus Liu GSK’s dream just turned into a nightmare. The company's BCMA-targeted Blenrep has failed in a phase 3 multiple myeloma trial, putting its accelerated approval in jeopardy. |
By Andrea Park These days, employer-sponsored wellness programs are a dime a dozen—but Verily may have hit the jackpot with its own Onduo virtual care platform. |
By Fraiser Kansteiner After similar moves in 2020 and 2021, Novartis’ generics arm on Monday said it would plug another 50 million euros (about $49.92 million) into its European production in a bid to boost capacity for finished dose form penicillins. In total, Sandoz has planned more than 250 million euros of investments in its continental antibiotics network. |
By Dave Muoio The Children's Hospital Association penned a letter of lame duck requests that included hundreds of millions for pediatric workforce training, the passage of legislation improving kids' access to care and protections on healthcare coverage for children. |
By Gabrielle Masson Boehringer Ingelheim has snagged former Novartis leader and Big Pharma vet Lykke Hinsch Gylvin, M.D., to serve as the company’s chief medical officer and head of global medicine. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| ResearchLearn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| WhitepaperRead through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| ResearchLearn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
